VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary L. Kepler who wrote (6618)	4/29/1999 12:07:00 AM
From: Vector1	Read Replies (4) of 9719

Gary, Been so damm busy it has been hard for me to participate much. I am closely following the portfolio however and and am very happy with its composition. INCY is oversold. It will have a nice big bump when the judge in the AFFX case denies the preliminary injunction. This should freeup micrarray sales. Apparently AFFX has sent a letter to INCY's customers saying that INCY's (Synteni's) chip technology violates AFFX's patents. Once the preliminary injuntion fails I believe chip sales will heat up quickly. I also expect a couple of deals announcing expansions of relationships with existing customers. GSII is so damm cheap that it is hard not to hold. They may have been denied trebble damages but they now should have a huge advantage in the balloon disection market. If they can't grow sales given the patent ruling they out to sell the company to someone who can. ICOS's value is way out of line with other biotechs and is a nice hedge for the portfolio. One slipup and they are looking at a 40% decline. Waiting for CLTR to commence its BLA is getting old. What I hear is that the company is saying that that the FDA wants the time between commencing a rolling fasttrack filing and finishing to be no more that 6 weeks. It would be nice if someone can confirm that. I still believe that they have a great molecule for NHL and that Bexxar will be a $300m drug in 2002. MLNM is the class of the genomics companies with top flight science, a tremendously leveraged business plan and huge funding. This is a stock you buy and forget. CGPI announced better that expected earnings and based on the latest Alex Brown report of a few days ago is already at an $11m run rate on Periostat sales. Very very impressive. SEPR is an enigma. Is it time to buy more. Peter S. if you are out there I would get your view. GZTC just announced that they cloned goats. This is huge because it potentially reduces the cost of creating transgenic animals. CELG is getting ready to explode. There is a lot of talk about angiogenisis. Thalidomid may be an early generation inhibitor of new blood vessels but it is approved (for effects of Leprosy)and is showing impressive results in a number of cancers and autoimmune disease. With expanded off label use based on published studies this could easily be a $100m drug within 12 months. Take a look at the CELG thread. it is one of the best on SI. Not overly verbose but very informative. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next